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1. INTRODUCTION 
Chronic kidney disease is a general term for heterogeneous disorders 
affecting the structure and function of the kidney. The variation in 
disease expression is related partly to cause and pathology, severity, and 
rate of progression. Since the introduction of the conceptual model, 
definition, and staging of chronic kidney disease 10 years ago,1-4 
guidelines have recommended a shift from kidney disease being 
recognized as a life threatening disorder affecting few people who need 
care by nephrologists, to a common disorder of varying severity that not 
only merits attention by general internists, but also needs a concerted 
public health approach for prevention, early detection, and 
management.4-6 Although guidelines had an important effect on clinical 
practice, research, and public health, they have also generated 
controversy.4,7 
Definitions and outcomes 
  
The definition of chronic kidney disease is based on the presence of 
kidney damage (i.e., albuminuria) or decreased kidney function (i.e., 
glomerular filtration rate [GFR] <60 mL/min per 1·73 m²) for 3 months or 
more, irrespective of clinical diagnosis.1,8-9 Because of the central role of 
GFR in the pathophysiology of complications, the disease is classified 
into five stages on the basis of GFR: more than 90 mL/min per 1·73 
m²(stage 1), 60–89 mL/min per 1·73 m² (stage 2), 30–59 mL/min per 1·73 
m² (stage 3), 15–29 mL/min per 1·73 m² (stage 4), and less than 15 
mL/min per 1·73 m² (stage 5). Findings from experimental and clinical 
studies have suggested an important role for proteinuria in the 
pathogenesis of disease progression.10 Epidemiological studies have 
shown graded relations between increased albuminuria and mortality 
and kidney outcomes in diverse study populations, in addition to, and 
independent of, low GFR and risk factors for cardiovascular disease.11-16 
Kidney failure is traditionally regarded as the most serious outcome of 
chronic kidney disease and symptoms are usually caused by 
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complications of reduced kidney function. When symptoms are severe 
they can be treated only by dialysis and transplantation; kidney failure 
treated this way is known as end-stage renal disease. Kidney failure is 
defined as a GFR of less than 15 mL/min per 1·73 m², or the need for 
treatment with dialysis or transplantation. Other outcomes include 
complications of reduced GFR, such as increased risk of cardiovascular 
disease, acute kidney injury, infection, cognitive impairment, and 
impaired physical function.17-20 Complications can occur at any stage, 
which often lead to death with no progression to kidney failure, and can 
arise from adverse effects of interventions to prevent or treat the disease. 
Chronic kidney disease: global dimension and perspectives21 
Epidemiology of chronic kidney disease 
 
According to the 2010 Global Burden of Disease study chronic kidney 
disease was ranked 27th in the list of causes of total number of global 
deaths in 1990 (age-standardized annual death rate of 15·7 per 100 000), 
but rose to 18th in 2010 (annual death rate 16·3 per 100 000).22 This 
degree of movement up the list was second only to that for HIV and AIDS. 
The overall increase in years of life lost due to premature mortality (82%) 
was third largest, behind HIV and AIDS (396%) and diabetes mellitus 
(93%). An analysis of data on cause of death in the USA and Australia by 
Rao and colleagues23 showed that a substantial pro portion of individuals 
who had died from diabetes had renal failure, but the cause of death was 
coded as diabetes without complication. In western countries, diabetes 
and hypertension account for over 2/3 rd of the cases of CKD.24 In India 
too, diabetes and hypertension today account for 40-60% cases of CKD.25 
Reported mortality from diabetes-related renal disease was estimated to 
be four to nine times less than the actual rate. 
The incidence and prevalence of end-stage kidney disease differ 
substantially across countries and regions. More than 80% of all patients 
receiving treatment for end-stage kidney disease are estimated to be in 
affluent countries with large elderly populations and universal access to 
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health care.26 The lower figures reported from poor countries are largely 
due to patients not being accepted into renal replacement therapy (RRT) 
programmes, although where economies are growing, the numbers of 
patients being accepted for RRT are rising strikingly.27 Projected 
worldwide population changes suggest that the potential number of cases 
of end-stage kidney disease will increase disproportionately in developing 
countries, such as China and India, where the number of elderly people 
are expanding. This effect will be enhanced further if the trends of 
increasing hypertension and diabetes prevalence persist, competing 
causes of death such as stroke and cardiovascular diseases are reduced, 
and access to treatment improves. In contrast to clinically apparent 
advanced-stage chronic kidney disease, precise calculation of the burden 
of less symptomatic or asymptomatic early-stage chronic kidney disease, 
which accounts for 80–90% of all cases, is difficult.28 
Although data on early-stage chronic kidney disease from 
different parts of the world, they are confounded by heterogeneity in the 
populations screened, methods used to determine glomerular filtration 
rate, and proteinuria assays. The estimates are usually based on a 
single-time measurement rather than on sustained demonstration of 
abnormality. Even within countries, subgroups are at increased risk of 
developing chronic kidney disease, disease progression, or both, 
including black and Asian people in the UK, black, Hispanic, and Native 
Americans in the USA, and Indigenous Australians, South American 
Aborigines, Maori, Pacific, and Torres Strait Islanders in New Zealand, 
and First Nation Canadians.29-31 
Demographic characteristics 
The demographics of people with chronic kidney disease vary widely 
worldwide. The mean age of 9614 patients presenting with stage 3 
chronic kidney disease in India was 51·0 (SD 13·6) years,32 whereas in 
1185 patients in China it was 63·6 (14·7) years.33 In India, patients with 
chronic kidney disease of unknown origin were younger, poorer, and 
more likely to present with advanced chronic kidney disease than were 
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people with known causes32. Young adults aged 20–50 years in sub-
Saharan Africa mainly develop chronic kidney disease owing to 
hypertension and glomerulonephritis34. In the USA, African American 
and Hispanic people reach end-stage kidney disease at younger ages 
than white people (mean age 57 and 58 years vs 63 years).29 
Causes 
Diabetes and hypertension are the leading causes ofchronic kidney 
disease in all developed and many developing countries but glomerular-
nephritis and unknown causes are more common in countries of Asia 
and sub-Saharan Africa. These differences are related mainly to the 
burden of disease moving away from infections towards chronic lifestyle-
related diseases, decreased birth rates, and increased life expectancy in 
developed countries.35 By contrast, infectious diseases continue to be 
prevalent in low-income countries, secondary to poor sanitation, 
inadequate supply of safe water, and high concentrations of disease-
transmitting vectors.36 Environmental pollution, pesticides, analgesic 
abuse, herbal medications, and use of unregulated food additives also 
contribute to the burden of chronic kidney disease in developing 
countries.37 Rapid urbanisation and globalisation have accelerated the 
transition in south Asian and Latin American countries, which has led to 
an overlap of disease burdens, with continued high prevalence of 
infectious diseases and an increasing prevalence and severity of lifestyle 
disorders, such as diabetes and hypertension.37-39 Genetic factors also 
contribute. Variations in MYH9 and APOL1 are associated with non-
diabetic chronic kidney disease in individuals of African origin. 
Identification of chronic kidney disease 
Identification and staging of chronic kidney disease rely on measurement 
of glomerular filtration rate and albuminuria. Calculation of actual 
glomerular filtration rate by measurement of external filtration markers 
is cumbersome and impractical. Values are, therefore, estimated on the 
basis of creatinine concentrations in plasma. Creatinine concentrations 
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in serum might also be affected by creatinine generation (dependent on 
muscle mass and dietary intake), tubular secretion, and extra renal 
removal and, therefore, variations between populations are expected. The 
Modification of Diet in Renal Disease study (MDRD) and Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) creatinine equations have 
correction factors for African Americans. Chinese, Japanese, and Thai 
investigators found that the MDRD equation underestimated the absolute 
glomerular filtration rates in populations from those countries and 
developed new equations or correction factors.40-42 The applicability of 
these modified equations to similar populations, such as the South 
Asians and most indigenous races, has not been widely explored. The 
accuracy of equations is affected by the reference method used to 
measure glomerular filtration rate. The MDRD and CKD-EPI equations 
were developed with ¹²⁵I-iothalamate clearance as the gold standard, the 
Chinese MDRD equation uses ⁹⁹mTc-diethylenetriaminepenta-acetic acid 
(⁹⁹mTc-DTPA) clearance, and the Japanese MDRD equation uses modified 
inulin clearance. In a head-to-head comparison study,⁹⁹mTc-DTPA 
clearance gave 10 mL/min per 1·73 m² higher values than did inulin 
clearance.43 These different approaches might substantially alter 
outcomes, as noted in the Japanese general population when two 
equations were used.44The characteristics of the population assessed 
during equation development can also affect accuracy. If an equation is 
developed in patients with advanced chronic kidney disease, output 
values are generally low.45 If the same equation were applied to the 
general population, an artificially high prevalence of low glomerular 
filtration rates would be seen. This feature led to the development of the 
CKD-EPI equation.46 The average glomerular filtration rate reference 
values for the MDRD and CKD-EPI cohorts assessed for equation 
development were 39·8 and 68·0 mL/min per 1·73 m², respectively. The 
MDRD equation showed 7·8% prevalence of chronic kidney disease in the 
National Health and Nutrition Examination Survey population, but the 
CKD-EPI showed a 6·3% prevalence.46 The 2012 KDIGO guideline 
suggests use of the CKD-EPI equation to calculate estimated glomerular 
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filtration rates in adults. Specific pediatric equations, which require 
knowledge of height, should be used to estimate glomerular filtration 
rates in children. Older equations, the most popular of which is the 
Cockroft-Gault formula, continue to be used in some areas. The accuracy 
of estimated glomerular filtration rate and albuminuria assessments is 
affected by biases in creatinine and urine albumin assays. Laboratories 
in many developing countries do not report estimated glomerular 
filtration rate values. Accurate assessment of differences by ethnic origin, 
region, or both, will require validation of existing equations for estimated 
glomerular filtration rate against the same glomerular filtration rate 
reference method and creatinine assay. In the meantime, the CKD-EPI 
equation is recommended to calculate estimated glomerular filtration 
rate, with recognition of the possibility of misclassification in some 
clinical settings and populations. 
 
Risk factors 
Chronic kidney disease is viewed as part of the rising worldwide non-
communicable disease burden. Hypertension, diabetes mellitus, and 
obesity are among the growing non-communicable diseases and are 
important risk factors for chronic kidney disease. The global prevalence 
of hypertension in adults was estimated to be about 26% (972 million 
cases) in 2000,47 with most cases (639 million [66%]) being in developing 
countries. Prevalence was 37%, 21%, and 20% in established market 
economies, India, and China respectively. In Latin America, 40·7% of men 
and 34·8% of women had hypertension, whereas in sub-Saharan Africa 
the values were 27·0% for men and 28·0% for women.47 Prevalence is 
higher in urban populations than in rural populations in developing 
countries.48 The worldwide hypertension prevalence, when age-specific 
and sex-specific adjustments are made to take into account changes in 
the world population, is projected to increase to 1·56 billion by 2025.47 
The actual number, however, might well exceed these projections, as 
suggested by a Canadian Hypertension Education Program Outcomes 
Research Task force study,49 which projected increases in prevalence of 
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25·7% and 60·0% between 1995 and 2005, respectively, in Ontario, 
Canada, after adjustment for age and sex. Moreover, rates of 
hypertension control are dismal. Pereira and colleagues50 showed that 
only 9·8% of men and 16·2% of women in developing, and 10·8% of men 
and 17·3% of women in developed countries had controlled hypertension. 
Similar trends are apparent for diabetes. The worldwide prevalence of 
diabetes in adults is estimated to be 6·4%, affecting 285 million people, 
and is expected to rise to 7·7% by 2030 (439 million cases).51 The largest 
increases in prevalence are expected in developing regions (the Middle 
East, 163%; sub-Saharan Africa, 161%; India, 151%; Latin America, 
148%; and China, 104%).52 Although diabetes is predicted to increase in 
all age strata, ageing populations and a shift towards urbanisation will 
contribute substantially. Similarly to hypertension, the projections are 
probably conservative, and could be exceeded by the actual growth.53 The 
prevalence of obesity worldwide is also increasing. 312 million adults 
worldwide were estimated to be obese at the beginning of the 21stcentury. 
Particularly alarming is the increase in the number of overweight and 
obese children. In contrast to the developed world, obesity in developing 
countries is rising in affluent and educated populations.54 
Herbs 
Herbal medicines are widely used by rural populations in Africa and Asia 
and have become popular in developed countries.55 Nephrotoxic effects 
can result from consumption of potentially toxic herbs, incorrect 
substitution of harmless herbs with toxic herbs, contamination with toxic 
compounds, such as heavy metals, or interactions between herbs and 
conventional treatments.56 Herbs can cause acute kidney injury, tubular 
dysfunction, electrolyte disturbances, hypertension, renal papillary 
necrosis, urolithiasis, chronic kidney disease, and urothelial cancer.55 
Herbal causes should be considered in cases of unexplained kidney 
disease, especially in areaswhere consumption of herbal preparations is 
high. Aristolochic-acid nephropathy is a progressive interstitial nephritis 
that leads to end-stage kidney disease and urothelial malignant disease. 
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It was first reported in 1993, Three clinical subtypes of aristolochic-acid 
nephropathy have been classified: chronic tubulointerstitial nephropathy 
(accounting for 93·3% of cases), acute kidney injury (4·3%), and tubular 
dysfunction with unchanged glomerular filtration rate (2·3%).57 The 
worldwide incidence of aristolochic-acid nephropathy is probably higher 
than initially thought. In Asian countries, where traditional medicines are 
very popular and pharmaceutical medicines are frequently substituted or 
supplemented by botanical products that include herbs containing 
aristolochic acid.58 
Infections 
HIV infection is epidemic in sub-Saharan Africa. Population screening 
has shown kidney involvement in 5–83% of HIV-infected individuals in 
this region.59-60 In the USA, HIV-associated nephropathy is seen in 
African Americans but not in white people. Despite a large HIV infected 
population, HIV-associated nephropathy is rare in Asia.61 The differences 
between regions could be explained by differential prevalence of high-risk 
alleles in MYH9 and APOL1.62-63 Early initiation of antiretroviral therapy 
reduces the burden of HIV-associated nephropathy but carries the risk of 
nephrotoxic effects, such as crystal-induced obstruction, tubular toxic 
effects, interstitial nephritis, lactic acidosis, and electrolyte disorders. 
Other specific infections that cause severe kidney lesions in populations 
worldwide include hepatitis B and C viruses. 
Water 
Various disorders directly or indirectly related to water can cause kidney 
disease. High temperatures frequently lead to water scarcity in tropical 
regions, which raises the risk of dehydration. Flowing water might be 
contaminated by heavy metals and organic compounds leached from soil, 
and grain in waterlogged fields can become contaminated with harmful 
substances.64 Many water borne diseases (eg, schistosomiasis, 
leptospirosis, scrub typhus, hanta virus, and malaria) affect the kidneys. 
Children are particularly vulnerable to acute kidney injury because of 
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diarrheal diseases.65 Enteric infections can cause haemolytic-uraemic 
syndrome, which eventually leads to the development of chronic kidney 
disease in a substantial proportion of affected individuals. In Germany an 
outbreak was triggered by Shigatoxin-producing Escherichia coli,66and in 
South Asia, haemolytic-uraemic syndrome is frequently seen after 
infection with Shigella dysenteriae.67 
Chronic kidney disease of unknown origin 
Clusters of cases of chronic kidney disease of unknown origin have been 
reported in some areas of Sri Lanka and India.27 The affected individuals 
are mainly young male farmers. Clinical presentation resembles that of 
interstitial nephritis. Histology shows interstitial fibrosis, tubular 
atrophy, and interstitial mononuclear-cell infiltration. Contamination of 
water, food, or both, by heavy metals, industrial chemicals, fertilizers, 
and pesticides has been suspected.68 Nevertheless, in a study funded by 
the Research and Prevention Committee of the International Society of 
Nephrology, no excess of heavy metals was found in the water in the 
Srikakulam district of India. 
Awareness of chronic kidney disease 
Despite its recognition as an important public health issue, awareness of 
chronic kidney disease remains low.69-70 In a nationwide health screening 
programme in the USA that involved around 90000 adults at high risk of 
chronic kidney disease, the prevalence and awareness rates were, 
respectively, 29·7% and 8·6% for white respondents, 22·8% and 6·3% for 
African Americans, 29·2% and 6·8% for Native Americans, 20·3% and 
11·1% for Hispanics, and 23·4% and 11·9% for Asians and Pacific 
Islanders.71Awareness was higher among people with advanced chronic 
kidney disease (overall 7·8% for stage 3 and 41·0% for stage 4) and those 
with diabetes, hypertension, and proteinuria.72 Furthermore, use of 
nephrology care was low, with less than 6% of participants with stage 3 
disease and less than 30% of those with stage 4–5 disease ever having 
seen a nephrologists. Low awareness has also been noted among health-
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care providers. In a nationwide audit adults followed up by general 
practitioners in Italy,70 only 17% had undergone serum creatinine 
testing, of whom 16% had glomerular filtration rates lower than 60 
mL/min per 1·73 m². Among these adults, chronic kidney disease had 
been correctly diagnosed in only 15%. In another study 525 hypertensive 
patients, 23% had chronic kidney disease, but general practitioners 
diagnosed it correctly in only 3·9%.73 Incorrect diagnosis results in 
delayed referrals to nephrologists, which leads to missed 
opportunities to implement strategies for slowing disease progression, 
cardiovascular protection, and preparation for RRT.74 Data suggest that 
increased awareness does not necessarily translate to improved 
outcomes. The risk of progression to end-stage kidney disease and death 
was higher among people aware of their chronic kidney disease status at 
entry into the US Kidney Early Evaluation programme. Adjustment for 
socioeconomic and clinical variables and presence of cardiovascular 
disease and cancer reduced the difference, but it remained significant.75 
Interactions with other disorders 
Cardiovascular mortality is ten to 30 times higher in individuals with 
end-stage kidney disease than in the general population when matched 
for age, ethnic origin, and sex. The association between chronic kidney 
disease and increased risk of cardiovascular disease is observed in high-
risk groups and in people in the general population with low glomerular 
filtration rates and albuminuria.76-78 The increased risks associated with 
low estimated glomerular filtration rates and albumin uria seem to be 
independent of each other. Furthermore, death seems to be a far more 
likely outcome than progression to end stage kidney disease in all stages 
of chronic kidney disease, and the high death rates might reflect 
accelerated rates of atherosclerosis and heart failure.79 Thus, individuals 
with chronic kidney disease should be viewed as being in the highest risk 
group for cardiovascular disease. Even among dialysis patients, decline 
in residual kidney function is associated with an increased risk of 
cardiovascular-related mortality and adverse outcomes.80 Additionally, 
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cardiovascular disease itself is a well recognised risk factor for 
chronic kidney disease and predicts progression to endstage kidney 
disease.76 
Acute kidney injury 
Patients with chronic kidney disease are at an increased risk of acute 
kidney injury.81 A transient increase in serum creatinine of as little as 27 
μmol/L increases the risk of death.82 Acute kidney injury might occur 
with the use of several medications, such as non-steroidal anti-
inflammatory drugs, several antibiotics, and angiotensin converting-
enzyme inhibitors, and, therefore, chronic kidney disease must be taken 
into account when drugs are being prescribed to enable adjustment or 
complete avoidance of specific drugs. Severe, long, and repeated episodes 
of acute kidney injury increase the risk of progression of chronic kidney 
disease. Despite different initial presentations and expression over time, 
chronic kidney disease and acute kidney injury should be viewed as 
parts of the same clinical syndrome related to reduced glomerular 
filtration rates. 
Socioeconomic effects and economicimplications 
The risk of chronic kidney disease is bi-directionally affected by level of 
economic development. Poverty increases the risk of disorders that 
predispose chronic kidney disease to develop or progress, and worsens 
outcomes in those who already have chronic kidney disease.  An analysis 
of National Health and Nutrition Examination Survey data showed that 
poverty is associated with an increased risk of protein uria even after 
correction for age, sex, ethnic origin, education, obesity, hypertension, 
diabetes, decreased glomerular filtration rate, and medication use.83 
People in the lowest socio-economic quartile are at a 60% greater risk of 
progressive chronic kidney disease than are those who are in the highest 
quartile.84 An interaction between ethnic origin and poverty has also been 
shown in minority and indigenous groups in many developed countries.29 
Chronic kidney disease imposes substantial economic burden on affected 
individuals, especially in developing countries. Their families experience 
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direct loss of income and changes in consumption patterns because of 
the spending of household finances on care and welfare costs. 
About 2–3% of the health-care expenditure in developed nations is used 
to provide treatment for patients with end stage kidney disease even 
though they account for only 0·1–0·2% of the total population; in 2010 
treatment costs accounted for 6·3% of the Medicare budget in the USA,85 
4·1% of the total health-care budget in Japan in 1996, and 3·24% of 
national health expenditure in South Korea in 2004.86 The economic 
costs associated with milder forms of chronic kidney disease are even 
higher. In India, the cost of a dialysis session varies from US$20 to $60, 
dependent on the type of facility.87 Some Indian states have started 
schemes to provide free RRT to the poor, but coverage is limited.27 Care of 
people with chronic kidney disease, particularly those who present for 
the first time with advanced disease, leads to catastrophic personal 
health expenditure in countries where treatment requires out-of-pocket 
spending. Patients frequently have to travel long distances, often with 
families, to receive specialized care.87 Most patients with end-stage kidney 
disease have complications at presentation and need emergency 
admission to hospital and dialysis.74 An analysis of the costs of treatment 
for 50 consecutive patients with end-stage kidney disease who underwent 
highly subsidised kidney transplantations in a public-sector hospital in 
India showed that 82% experienced financial crisis during treatment and 
more than half (56%) of patients lost their jobs. 
 
Kidney Disease Quality of Life Questionnaire 
The Kidney Disease Quality of Life Questionnaire (KDQOL) (and its 
shorter version, the KDQOL-SF) is one of the most widely-used 
instruments in assessing the quality of life of patients with ESRD.88-90 
Developed at RAND, the KDQOL is a composite of a previously existing 
instrument and newly-developed questions targeted specifically to kidney 
dialysis. As such, it is both a generic and a disease-specific instrument. 
Development of the disease-specific components was based on the results 
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of Hays’ work with focus groups of patients with ESRD. The 
symptoms/problems scale assesses muscle soreness, back/chest pain, 
headaches, cramps, bruising, itchy skin, shortness of breath, dizziness, 
lack of appetite, excessive thirst, numbness of hands and feet, trouble 
with memory, blurred vision, nausea and clotting, or other problems 
associated with the vascular access site. A second segment addresses 
daily concerns: dietary and fluid restrictions, impact of dialysis on work 
or family responsibilities, travel, lifting objects, personal appearance and 
ability to accomplish fewer tasks than normal. A third segment addresses 
work-related difficulties. Additional items were taken from already-
existing instruments: cognitive function items from the SIP,91 quality of 
social interaction from the Functional Status Questionnaire,92 sexual 
function from the MOS Sexual Function Scale,93 sleep dysfunctionfrom 
the SIP Sleep subscale,51 and a previously-existing social support scale.94 
An additional six items eliciting responses to dialysis staff 
encouragement were written exclusively for Hays’ study. Finally, patient 
satisfaction was also measured using two items from The Chiropractic 
Questionnaire.95 The totalinstrument contains 134 items. Due to the 
length of the KDQOL, a shorter version has been created.96 The KDQOL-
SF, also developed at RAND, contains the SF-36 core, as well as an 
additional 44 items targeted toward kidney disease and patient 
satisfaction, as listed above. Korevaar and colleagues have recently 
published the first validation study of the KDQOL-SF in a cohort of 
Dutch dialysis patients.90 
HRQOL among dialysis modalities 
The findings comparing dialysis with transplant patients are those 
comparing HRQOL among patients receiving various dialysis modalities. 
Studies comparing HD and PDhave yielded mixed results. Evans’ 1985 
study reported those receiving home HD or PD maintained a HRQOL 
higher than those receiving in-center HD.97 Similarly, using multiple 
instruments Simmons compared a group of patients on PDwith a group 
on in-center HD and found the PD group had better scores in physical, 
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social and emotional arenas.98 Merkus found mental health to be 
superior in PD patients compared with HD patients.99 In contrast, Mittal 
and colleagues found physical health and function were lower in patients 
receiving PD compared with HD.100 Korevaar and colleagues assessed 
HRQOL with the SF-36 and the EuroQoL, in pre-dialysis ESRD patients 
at the initiation of therapy and found significant baseline differences 
between those initiating HD versus PD, lending credence to the idea that 
there are underlying differences between patient groups prior to dialysis 
initiation.101 The use of the disease-specific.102 
HRQOL in early versus late diagnosis of ESRD 
Sesso and Yoshihiro used several instruments in their study measuring 
HRQOL in patients with ESRD who were diagnosed early (≥6 months 
before dialysis initiation) versus late (≤1 month) with chronic renal 
failure.103 They found a significant between-group difference in the 
symptoms of depression, relationships and frustration dimensions. 
Functional status declined compared with 1 year prior to dialysis, 
particularly in the late diagnosis group. Elderly patients were particularly 
affected by these differences. Of note, however, is that several of these 
differences had diminished after an average of 9 months of dialysis 
treatment.103 
Relationship between dialysis adequacy &HRQOL 
Hamilton used the SF-36 and the KDQ to study whether dialysis 
adequacy corresponded with HRQOL.104 Although their pilot study 
demonstrated that improvements in dialysis adequacy paralleled 
improvements in HRQOL over a period of 3 months, the authors 
cautioned that there were too many competing explanations of the results 
to definitively attribute adequacy to improved HRQOL. 
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2. LITERATURE REVIEW 
Pereira B et al.,105 aimed to evaluate the prevalence of anxiety, 
depression, stress, fatigue, social support, and quality of life in patients 
with CKD and their caregivers. A cross sectional study was conducted 
with 21 patients and their caregivers, from January to September 2015. 
The study included patients aged over 18 years, with at least 6 months 
on dialysis treatment, and caregivers who were family members. The 
participant’s social, demographic, clinical, laboratory, and psychological 
variables were evaluated. 38.1% had symptoms that indicated anxiety 
and depression. The average score for practical social support was 
3.15 ± 0.769 and that for emotional social support was 3.16 ± 0.79. As for 
fatigue, 14.3% of patients reported being ‘extremely tired’ and 14.3% 
reported that they engaged in all the activities they usually performed 
before the illness. Further, 57.1% presented stress, and of these, 66.7% 
were at the resistance stage, with predominance of psychological 
symptoms in 60.0%. The quality of life domain in terms of functional 
capacity (FC) presented a correlation with haemoglobin level (r = 0.581, 
p = 0.006) and non-anaemic patients presented better FC. Among 
caregivers, we observed symptoms that indicated anxiety and depression 
in 33.3% of the sample. Caregivers exhibited an average score of 
2.88 ± 0.77 for practical social support and 3.0 ± 0.72 for emotional social 
support. Further, 14.3% reported being ‘extremely tired’ and 28.8% 
reported that they engaged in all activities that they usually performed 
before the patient’s illness. While comparing the two groups, (patients vs. 
caregivers), they presented similar results for the presence of anxiety, 
depression, and fatigue. The mental health characteristics of patients 
and caregivers were similar, and within the context of dialysis for renal 
disease, both must undergo specific interventions. 
Senanayake SJ et al.,106 conducted a community based cross-sectional 
study included a representative sample of 1174 registered CKD patients 
from all 19 Medical Officer of Health areas in the District of 
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Anuradhapura. Trained paramedical staff visited the households and 
administered an interviewer administered questionnaire to gather 
information. A total of 1118 CKD patients participated. Mean age was 
58.3 (SD 10.8) years. Fifty nine (5.3%) patients had been hospitalized 
during the six months preceding data collection. The total OOP for a 
hospital admission for one patient was Rs. 3625 (IQR 1650-8760). Thirty 
eight (3.4%) patients were on dialysis. The median direct cost per patient 
for an episode of dialysis was Rs.595 (IQR 415-995) while the median 
direct cost for a dialysis patient per month was Rs.5490 (IQR 3950-
10934). In the study population a total of 1095 (98.0%) had attended 
clinic at least once during the six months preceding the study. The OOP 
expenditure for a single clinic visit for one patient was Rs.434 (IQR 200- 
860).CKDpatients living in the Anuradhapura District spent significant 
amounts on accessing health care which can worsen their economic 
hardships. Planned interventions are warranted in order to improve their 
quality of life and financial situation. 
Lemos CF et al.,107 evaluated the quality of life (QOL) using the generic 
instrument SF-36 in patients with CKD in pre-dialysis and identify the 
possible influence of the degree of renal function, hemoglobin level, age, 
gender, family income and level of education on QOL. A cross-sectional 
study was conducted and included 170 individuals (83 men) with a mean 
age of 57 ± 15 years who met the inclusion criteria and answered the SF-
36. Laboratory tests and clinical and demographic data were obtained, 
and the glomerular filtration rate was estimated using the CKD-EPI 
formula. The degree of renal function did not influence QOL. Women had 
lower scores in functional capacity, physical aspects, pain, and mental 
health. Patients younger than 47 years old showed better QOL in the 
functional capacity; however, their QOL was worse in terms of social 
aspects. Subjects with an income higher than 5.1 times the minimum 
wage had better QOL in the functional capacity, pain, social, physical 
and emotional roles, and mental health. Hemoglobin levels and education 
did not globally influence QOL.Gender and age influenced QOL, but 
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family income was the most important factor affecting QOL (6 out of 8 
domains investigated by SF-36) in this sample of 170 individuals with 
CKD in pre-dialysis. These findings suggest that many efforts should be 
made to reduce the effect of these factors on quality of life in patients 
with CKD and reinforce the need for longitudinal studies and 
intervention. 
Brown MA et al.,108 examined the outcome of patients with renal 
supportive care without dialysis (RSC-NFD) and those planned for or 
commencing dialysis. In this prospective observational study, symptoms 
were measured using the Memorial Symptom Assessment Scale and the 
Palliative care Outcomes Scale - Symptoms (renal) inventory and QOL 
was measured using the Short Form-36 survey. 273 pre-dialysispatients 
who had usual nephrology care and 122 non-dialysis patients were 
enrolled in the study. A further 72 patients commenced dialysis during 
study period without attending either clinic. Non-dialysispatients were 
older than the pre-dialysis group (82 vs 67 years; P<0.001) but had 
similar eGFR at the first clinic visit (16 ml/min per 1.73 m(2); P=0.92). 
Compared with the RSC-NFD group, the death rate was lower in the pre-
dialysis group who did not require dialysis. Median survival in RSC-NFD 
patients was 16 (interquartile range, 9, 37) months and 32% survived 
>12 months after eGFR fell below 10 ml/min per 1.73 m(2). For the whole 
group, age, serum albumin, and eGFR<15 ml/min per 1.73 m(2) were 
associated with poorer survival of the non-dialysis patients, 57% had 
stable or improved symptoms over 12 months and 58% had stable or 
improved QOL. Elderly patients who choose not to have dialysis as part 
of shared decision making survive a median of 16 months and about one-
third survive 12 months past a time when dialysis might have otherwise 
been indicated.  
Lee SJ et al.,109 intended to examine the prevalence of frailty and 
investigate the contribution of frailty to quality of life in pre-dialysis CKD 
patients in Korea. Using a cross-sectional survey design, data were 
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collected at an outpatient CKD clinic in a general hospital in Korea. The 
frailty criterion was modified from previous studies. The Short Form-36 
Health Survey version 2 was used to measure physical and mental 
component summary scores. Data were analyzed using chi-square, t-
tests, and hierarchical linear regression. Of the 168 CKD patients, 63 
(37.5 %) were frail. Frail patients were significantly older and had lower 
physical and mental quality of life than those who were non-frail. In 
hierarchical regression evaluating the influence of frailty on physical and 
mental quality of life, the initial model was significantly improved when 
frailty was included. Frail patients had lower physical and mental quality 
of life. Frailty affected both physical and mental quality of life in pre-
dialysis patients with CKD. More attention should be paid to the 
potential role of early detection and prevention of frailty to improve 
patients’ quality of life. 
Fassbinder et al.,110 compare the physical fitness and quality of 
life of patients with chronic kidney disease submitted on hemodialysis 
(G1) and pre-dialysis treatment (G2). A cross-sectional study, 
54 patients with CKD, 27 of the G1 group (58.15 ± 10.84 years), 27 of G2 
group (62.04 ± 16.56 years). There were cardiovascular risk factors, 
anthropometric measurements, respiratory muscle strength was 
measured by the inspiratory pressure (MIP) and expiratory (MEP) 
maximum measured in the manometer, six-minute walk (TC6'), 
cardiopulmonary exercise test, sit and stand one minute test (TSL1') and 
the Short-Form Questioner (SF-36) to assess QOL. 
The patients presented disease of stage between 2 and 5. It was applied 
the Kolmogorov-Smirnov normality test and used the t (Student) test or 
the U (Mann Whitney) test to compare the means of quantitative 
variables and the chi-square Pearson test and Fisher's exact test for 
qualitative variables. Pearson's or Spearman's test was used to identify 
correlations. No statistically significant difference was found between G1 
and G2 in VO2peak (p = 0,259) in TC6' (p = 0,433) in the MIPmax (p = 
0,158) and found only in the MEPmax (p = 0,024) to G1. The scores of 
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the SF-36 in both groups showed a worse health status as evidenced by 
the low score in scores for QOL. Patients with CKD had reduced 
functional capacity and QOL, and hemodialysis, statistically, didn't have 
showed negative repercussions when compared with pre-
dialysis patients. 
Ho SE et al.,111 examined the quality of life amongst the end 
stage renal disease (ESRD) hemodialysis patients in Malaysia. A cross 
sectional descriptive study was conducted on 72 ESRD patients at a 
Dialysis Centre in Malaysia. The modified KDQOL-SF™ subscales, kidney 
disease-targeted scale and 36 item health survey scale questionnaires 
were used. The overall health rating was 66.73 ± 11.670 indicating 
good quality of life. There was no significant difference between quality of 
life for the different domains according to gender (p >0.05).A significant 
difference between quality of life in the domain of burden of kidney 
disease. Physical functioning deteriorated significantly with age (p=0.012) 
while social functioning was lowest in the 50-65 years age group 
(p=0.037). Those who had no morbidities had significantly better scores 
on the effects of kidney (p=0.036), burden of kidney disease (p=0.011) 
and physical functioning (p=0.025). Patients undergoing hemodialysis 
have been found to have good quality of life despite having ESRD. It is 
therefore of paramount importance to constantly monitoring the standard 
of care for these patients to enable them to live their life to the fullest. 
Abraham S et al.,112  intended to revealed that patient education can 
play a significant role in improving the QOL in these patients. The 
primary objective of the study was to assess the QOL of patients on 
hemodialysis by using the World Health Organization Quality of Life 
assessment scale and also to study the impact of patient counselling in 
these patients. Fifty patients were selected for the study and they were 
randomly divided into two groups, control and test; counselling was given 
to the test group of patients. There was an increase in score in all the 
four domains (physical, psychological, environmental and social) among 
the test group when compared with the control group. The psychological 
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domain showed significant increase in score compared with others. 
Findings demonstrate that patient counseling plays an important role in 
improving the QOL by changing their psychological thinking and bringing 
them toward spirituality. 
Wyld M et al.,113 conducted a systematic review, meta-analysis, and 
meta-regression of peer-reviewed published articles and of PhD 
dissertations published through 1 December 2010 that reported utility-
based quality of life (utility) for adults with late-stage CKD. Studies 
reporting utilities by proxy (e.g., reported by a patient's doctor or family 
member) were excluded. In total, 190 studies reporting 326 utilities from 
over 56,000 patients were analyzed. There were 25 utilities from pre-
treatment CKD patients, 226 from dialysis patients 
(haemodialysis, n = 163; peritoneal dialysis, n = 44), 66 from kidney 
transplant patients, and three from patients treated with non-dialytic 
conservative care. Using time tradeoff as a referent instrument, kidney 
transplant recipients had a mean utility of 0.82 (95% CI: 0.74, 0.90). The 
mean utility was comparable in pre-treatment CKD patients 
(difference = −0.02; 95% CI: −0.09, 0.04), 0.11 lower in dialysis patients 
(95% CI: −0.15, −0.08), and 0.2 lower in conservative care patients (95% 
CI: −0.38, −0.01). Patients treated with automated peritoneal dialysis had 
a significantly higher mean utility (0.80) than those on continuous 
ambulatory peritoneal dialysis (0.72; p = 0.02). The mean utility of 
transplant patients increased over time, from 0.66 in the 1980s to 0.85 
in the 2000s, an increase of 0.19 (95% CI: 0.11, 0.26). The main 
limitations of this study were that treatment assignments were not 
random, that only transplant had longitudinal data available, and that 
we calculated EuroQol Group EQ-5D scores from SF-36 and SF-12 
health survey data, and therefore the algorithms may not reflect EQ-5D 
scores measured directly. For patients with late-stage CKD, treatment 
with dialysis is associated with a significant decrement in quality of life 
compared to treatment with kidney transplantation. These findings 
provide evidence-based utility estimates to inform economic evaluations 
Assessment Of Quality Of Life In Dialysis And Non-Dialysis Chronic Kidney 
Disease patients 
 
Department of Pharmacy Practice                             21                 J.K.K. Nattraja College of Pharmacy 
 
of kidney therapies, useful for policy makers and in individual treatment 
discussions with CKD patients. 
Cruz MC et al.,114 conducted a study to compare the dimensions of 
quality of life in the stages of chronic kidney disease and the influence of 
socio demographic, clinical and laboratory data. A total of 155 chronic 
kidney failure patients were enrolled of which 36 were undergone 
hemodialysis. Quality of life was rated by the Medical Outcomes Study 
Short Form 36-Item (SF-36) and functional status by the Karnofsky 
Performance Scale. Clinical, laboratory and socio demographic variables 
were investigated. They found that quality of life decreased in all stages of 
kidney disease. A reduction in physical functions, physical role 
functioning and in the physical component summary was observed 
progressively in the different stages of kidney disease. Individuals with 
higher educational level who were professionally active displayed higher 
physical component summary values, whereas men and those with a 
higher income presented better mental component summary values. 
Older patients performed worse on the physical component summary and 
better on the mental component summary. Three or more comorbidities 
had an impact on the physical dimension. They found quality of life is 
decreased in renal patients in the early stages of disease. No association 
was detected between the stages of the disease and the quality of life. It 
was possible to establish socio demographic, clinical and laboratory risk 
factors for a worse quality of life in this population. 
Mujais SK et al.,115 investigated the determinants of health-related 
quality of life (HRQOL) in chronic kidney disease (CKD) patients not on 
dialysis. A prospective study was undertaken of HRQOL in a cohort of 
1186 CKD patients cared for in nephrology clinics in North America. 
Baseline and follow-up HRQOL were evaluated using the validated 
Kidney Disease Quality Of Life instrument. Baseline measures of HRQOL 
were reduced in CKD patients in proportion to the severity grade of CKD. 
Physical functioning score declined progressively with more advanced 
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stages of CKD and so did the score for role-physical. Female gender and 
the presence of diabetes and a history of cardiovascular co-morbidities 
were also associated with reduced HRQOL (physical composite score: 
male: 41.0 ± 10.2; female: 37.7 ± 10.8; P< 0.0001; diabetic: 37.3 ± 10.6; 
non-diabetic: 41.6 ± 10.2; P< 0.0001; history of congestive heart failure, 
yes: 35.4 ± 9.7; no: 40.3 ± 10.6; P< 0.0001; history of myocardial 
infarction, yes: 36.1 ± 10.0; no: 40.2 ± 10.6; P< 0.0001). Anemia and beta 
blocker usage were also associated with lower HRQOL scores. HRQOL 
measures declined over time in this population. The main correlates of 
change over time were age, albumin level and co-existent co-morbidities. 
The observations profound CKD has impact on HRQOL and suggests 
potential areas that can be targeted for therapeutic intervention. 
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3. NEED OF THE STUDY 
The incidence and prevalence of patients with chronic kidney disease 
(CKD) is increasing worldwide. HEALTH-RELATED quality of life (QOL) 
has been defined in different ways over the years. The World Health 
Organization (WHO) has defined QOL as "an individual's perception of 
their position in life in the context of the culture and value systems in 
which they live and in relation to their goals, expectations, standards and 
concerns”. In fact, QOL is an important outcome that is used as a 
valuable parameter of health and well-being. Research findings have 
shown that lower scores on QOL were strongly associated with higher 
risk of death and hospitalization than clinical parameters such as serum 
albumin levels in cases of CKD patients.This is despite the factsobtained 
from various studies that have shown the patient with CKD had lower 
QOL compared to the healthy individuals. Therefore, improving CKD 
patients’ life span as well as QOL is of utmost importance. Health-related 
QOL includes physical, psychological, and social domains of health, each 
of which includes a diversity of components. Moreover, each component 
can be expressed in different ways according to the subjective perception 
of each patient, resulting in a different assessment of QOL. Therefore, 
two patients with similar clinical and therapeutic conditions may assess 
QOL differently because the concept is the result of the interaction 
between the patient’s life conditions and the way in which these are 
perceived by the patient.88, 115-118 
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4. AIM AND OBJECTIVES 
Aim 
 The aim of the study is to assess quality of life in dialysis and non-
dialysis chronic kidney disease patients. 
Objectives 
1. To study the demographic details of patients with Chronic Kidney 
Disease and Dialysis Patients. 
2. To study the Prevalence of symptoms in patients with Chronic 
Kidney Disease and Dialysis Patients. 
3. Determine the quality of life ofpatients with Chronic Kidney 
Disease and Dialysis Patients by using Kidney Disease Quality of 
Life Questionnaire–Short Form (KDQOL-SFTM). 
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5. METHODOLOGY 
Study design: Observational and prospective study. 
Study population comprised of 200 patients with CRF sampled from 
nephrology department of a tertiary care hospital, Erode. CRF patients 
undergoing dialysis and not on dialysis aged 18 years and above of either 
sex and be able to provide informed consent to participate were included 
in the study. The patients who had undergone renal transplant were 
excluded. Participation in the study was voluntary and data was gathered 
from November 2016 through August 2017. The complete project was 
carried out according to the permission granted by the Institutional 
Human ethics committee. Written consent was obtained from 
participants prior to study. Demographic data recorded were age, gender, 
educational status, financial status and co-morbidities. KDQOL-SFTM was 
administered to CRF patients divided into two groups CRF on dialysis 
(CRF-D, n = 74) and CRF not on dialysis (CRF-ND, n = 126). 
Survey Instrument 
The disease – specific instrument used in this study was the Kidney 
Disease Quality of Life –short form (KDQOL-SFTM) version 1.3, from 
RAND Corporation a self – report measure developed for CRF patients.88 
The KDQOL-SFTM was available in English version. 
Even though KDQOL-SF™ is a self-reported questionnaire, considering 
the high proportion of illiterate participants, in this study questionnaires 
were   administered by an interview to all the study participants. 
The SF 36 assesses the HRQOL in eight domains (physical functioning, 
role limitations caused by physical problems,role limitations caused by 
emotional problems, pain,general health, energy/fatigue, emotional well-
being,and social function).  
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The KDQOL-SFTM includes multi-item scales targeted at the particular 
health-related concerns of individuals who have kidney disease and are 
on dialysis.  
KDQOL-SFTMis a multidimensional, reliable and validated questionnaire 
intended for dialysis patients. It has 43 domains targeted for ESRD (43 
items) and has as its generic core the 36 domain of the short form health 
survey (SF-36).  Domains, on a 100-point scale, are generally measured 
with these questions, including (1) burden of kidney disease; (2) cognitive 
function; (3) dialysis staff encouragement; (4) effects of kidney disease; (5) 
patient satisfaction; (6) quality of social interaction; (7) sexual function; 
(8) sleep; (9) social support; (10) symptom problem; and (11) work status. 
Since our patient population comprised on CRF patients on dialysis and 
not on dialysis, two questions relating to dialysis staff encouragement 
and patient satisfaction that are generally part of the disease-specific 
component of the KDQOL-SFTM were excluded as they were not relevant 
to the population under evaluation as reported by Mujais et al., 2009.115 
Question related to sexual function question was also eliminated. 
Scoring algorithm was used to calculate scores ranging from 0 to100. The 
scores represent the percentage of total possible score achieved, with 100 
representing the highest quality of life. 
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6. RESULTS 
DEMOGRAPHIC CHARACTERISTICS OF STUDY POPULATION 
Table 1. Gender wise distribution of Study population 
Sl.No Gender CRF-ND(n=126) CRF-D(n=74) 
1 Male 71(56.3%) 44(59.4%) 
2 Female 55(43.6%) 30(40.5%) 
Data are reported as number (%) 
 
Figure 1. Gender wise distribution of Study population 
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Table 2. Age wise distribution of Study population 
Sl.No Age (in years) CRF- ND(n=126) CRF- D(n=74) 
1 <40 21(16.6%) 09(12.1%) 
2 41-50 27(21.4%) 13(17.5%) 
3 51-60 31(24.6%) 19(25.6%) 
4 >60 47(37.3%) 33(44.5%) 
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Table 3. Co-morbidities in study population 
 
 
Figure 3. Co-morbidities in study population 
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Sl.No Co-morbidities CRF- ND(n=126) CRF- D(n=74) 
1 Hypertension 107(84.9%) 69(93.2%) 
2 Ischemic Heart Disease 63(50.0%) 47(63.5%) 
3 Diabetes Mellitus 93(73.8%) 59(79.7%) 
4 Anaemia 98(77.7%) 63(85.1%) 
5 Others 47(37.3%) 27(36.4%) 
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Table 4. Educational level of study population 
Sl. No Educational status CRF- ND(n=126) CRF- D(n=74) 
1 Illiterate 53(42.0%) 31(41.8%) 
2 School 45(35.7%) 25(33.7%) 
3 Degree 28(22.2%) 18(24.3%) 
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Table 5 .Individual monthly income of study population 
Sl.no 
Monthly per capita 
Income(INR) 
CRF-
ND(n=126) 
CRF- D(n=74) 
1 <5000 48(38.0%) 28(37.8%) 
2 5000 – 15000 64(50.7%) 37(50.0%) 
3 >15000 14(11.1%) 09(12.1%) 
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Table 6. Marital status of study population 
Sl.no Marital Status CRF- ND(n=126) CRF- D(n=74) 
1 Married 95(75.3%) 56(75.6%) 
2 Divorced 22(17.4%) 11(14.8%) 
3 Single 9(7.1%) 7(9.4%) 
 
Figure 6. Marital status of study population 
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Table 7. Laboratory data of study population 
Sl.no Laboratory Data 
CRF- ND 
(Mean ± SD) 
CRF- D 
(Mean ± SD) 
P Value 
1 Hb(g/dl)* 11.7±1.2 11.2±1.8 0.01 
2 Serum Urea(mg/dl)* 82.4± 32.9 127±30.3 0.03 
3 
Serum calcium 
(mg/dl)* 
9.1±0.5 9.0±1.0 0.01 
4 
Serum albumin 
(mg/dl)* 
3.8±0.5 3.6±0.6 0.04 
5 
Serum Phosphorous 
(mg/dl)* 
4.1±0.7 4.9±0.8 0.01 
*P<0.05. CKD  ND: CKD –D  
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Table 8. Prevalence of symptoms in study population 
Sl.no 
Prevalence of 
symptoms 
CRF- 
ND(n=126) 
CRF- D(n=74) P  Value 
1 
Feeling tired and lack 
of energy 
108(85.7%) 55(74.3%) 0.41 
2 Worrying 87(69.0%) 41(55.4%) 0.82 
3 Trouble in sleep 73(57.9%) 30(40.5%) 0.37 
4 Itching 92(73.0%) 55(74.3%) 0.81 
5 Feeling depressed* 41(32.5%) 19(25.6%) 0.03 
6 Bone and joint pain 43(34.1%) 21(28.3%) 0.77 
7 Muscle cramps 83(65.8%) 42(56.7%) 0.15 
8 Dry mouth 79(62.6%) 37(50.0%) 0.04 
9 Constipation 31(24.6%) 26(35.1%) 0.44 
10 Swelling legs 29(23.0%) 11(14.8%) 0.11 
11 Feeling nervous 41(32.5%) 21(28.3%) 0.25 
12 Headache 47(37.3%) 22(29.7%) 0.12 
13 Diarrhea 31(24.6%) 14(18.9%) 0.68 
14 Decreased appetite 41(32.5%) 20(27.0%) 0.43 
15 Cough 44(34.9%) 21(28.3%) 0.67 
16 Nausea 43(34.1%) 22(29.7%) 0.19 
17 Vomiting 41(32.5%) 24(32.4%) 0.61 
18 Numbness in feet 51(40.4%) 28(37.8%) 0.18 
19 Suppressed breathing* 40(31.7%) 19(25.6%) 0.01 
20 
Decreased interest in 
sex 
27(21.4%) 16(21.6%) 0.27 
*P<0.05. CKD  ND: CKD –D  
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Figure8. Prevalence of symptoms in study population 
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Table 9. KDQOL domain scores in study population 
Sl.no 
Kidney disease- 
specific domains 
CRF- ND 
(Mean±SD) 
CRF- D 
(Mean±SD) 
P  
Value 
1 Symptoms/problems 79.37±14.11 77.35±12.25 0.60 
2 Effect of Kidney Disease 66.13±14.07 74.66±13.44 0.11 
3 
Burden of kidney 
disease 
27.41±17.06 34.15±21.07 0.55 
4 Work status 43.43±26.15 40.39±32.62 0.12 
5 Cognitive 72.91±18.19 62.52±20.17 0.23 
6 
Quality of social 
interaction 
77.66±20.42 75.91±19.72 0.22 
7 Sleep 65.88±22.28 65.22±18.37 0.29 
8 Social support 86.15±22.71 78.21±23.86 0.16 
 
Figure 9. KDQOL domain scores in study population 
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Table 10 .SF 36 items health survey scalescore in study population 
Sl.No 
SF 36 items 
health survey 
scales 
CRF- ND 
(Mean± SD) 
CRF- D 
(Mean± SD) 
P  Value 
1 Physical Function 45.66±25.17 50.17±38.11 0.14 
2 Role - physical 39.13±21.67 45.66±31.00 0.24 
3 Pain 51.66±34.33 59.13±33.52 0.16 
4 General health 24.17±11.65 30.66±15.14 0.11 
5 
Emotional well 
being 
56.17±19.41 55.41±18.66 
0.02 
6 Role -emotional 64.36±35.42 68.17±30.47 0.01 
7 Social function 78.11±27.09 66.86±28.38 0.02 
8 Energy/Fatigue 51.36±10.39 40.66±15.33 0.15 
 
Figure 10.SF 36 items health survey scale score in study population 
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7. DISCUSSION 
Measuring the impact of CRF treatment on patients’ quality of life is 
being recognized as an important outcome measure. The main aim along 
with treatment in patients with chronic medical conditions, such as CRF, 
in particular, is to reduce disease burden and suffering caused by 
thedisease. This means to improve the overall wellbeing of the patient 
and to improve the individual’s quality of life. The Kidney Disease Quality 
of Life Questionnaire–Short Form (KDQOL-SFTM) has become themost 
widely used QOL measures for CRF patients. In this study Quality of Life 
compared using KDQOL-SFTM scores among patients with dialysis and 
different CKD stages to study the relationship between QOL and the risks 
of outcomes. A total of 200CRF patients participated in the study which 
included 74CRF patients on dialysis (CRF-D) and 126CRF patients not 
on dialysis (CRF-ND). 
Table no. 1, shows the gender wise distribution of Study population. 
Overall 59.4% were male patients greater in number than female 40.5% 
in CRF-D group, whereas CRF-ND comprised of 56.3% male patients and 
43.6% of female. 
Table no. 2, shows theage wise distribution. In this most of the CRF-D 
patients were in the age group of more than 60 years (44.5%) followed by 
51-60 years (25.6%),41-50 years (17.5%) and less than 40 
years(12.1%).CRF-ND patients were more in the age group of more than 
60 years (37.3%) followed by 51-60 years (24.6%),41-50 years (21.4%)and 
less than 40 years(16.6%). 
In both the groups, most of the participants were over 60 years. 
Table no. 3, shows the co-morbidities of the study population. 
Hypertension, Ischemic Heart Disease, Diabetes Mellitus, and Anaemia 
are the co-morbid diseases commonly found with the CKD patients. In 
this study most of the CRF-D patients have hypertension(93.2%), 
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followed by anaemia (85.1%), Diabetes mellitus (79.7%), Ischemic Heart 
Disease (63.5%) and other diseases (36.4%). 
Most of the CRF-ND patients have hypertension(84.9%), followed by 
anaemia (77.7%), Diabetes Mellitus (73.8%), Ischemic Heart Disease 
(50.0%) and other diseases (37.3%). 
Table no. 4, shows the educational level of study population. 41.8%(CRF-
D) and 42.0% (CRF-ND) patients were mostly Illiterates. 35.7% (CRF-ND) 
and 33.7% (CRF-D) of patients had education up to school level. Only 
20% of the study population completed degree. 
Table no. 5, shows theindividual monthly income.50% of the CRF-D 
andCRF-ND patients getting an income of 5000-15000 per month. Only 
CRF-D (12.1%) and CRF-ND (11.1%) have monthly wage of 15000. 
Table no. 6, shows the marital status of study population. About 75% of 
the CRF-D and CRF-ND patients are married. CRF-D(9.4%) and CRF-ND 
(7.1%) patients are single in the study population. 
Table no. 7, shows the laboratory data of study population. Heamoglobin, 
serum urea, serum albumin, serum phosphorous and serum calcium 
shows a significant difference in the CRF-D andCRF-ND patients. 
Table no. 8, shows the prevalence of symptoms in study population. 
Feeling tired and lack of energy, worrying, Itching, feeling depressed, 
bone and joint pain,muscle cramps, dry mouth, constipation, swelling 
legs, feeling nervous, headache, diarrhea, decreased appetite, nausea, 
vomiting, numbness in feet, suppressed breathing, decreased interest in 
sex are the prevalence of symptoms associated with the study population.  
The most prevalent symptoms in the dialysis groups were feeling tired 
and lack of energy (74.3%),itching (74.3%)Worrying (55.4%),and muscle 
cramps (56.7%); whereas then on-dialysis group commonly experienced 
feeling tired and lack of energy (85.7%), worry (69.0%), itching (73.0%) 
and muscle cramps (65.8%). Feeling tired and lack of energy(fatigue) was 
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the most prevalent symptom across all groups. In this study, nausea and 
decreased appetite were reported frequently.Our findings show that some 
symptom burden was higher in the non-dialysis group, compared to the 
dialysis group but most of the symptoms are did not reach statistical 
significance. Feeling depressed (p<0.03) and suppressed breathing 
(p<0.01) have significant difference in the CRF-D and CRF-ND patients. 
For instance, the most prevalent symptoms are not necessarily the most 
severe ordistressing symptoms, and that other symptoms are less 
important in respect of their severity but are frequently experienced.  
CRF patients not on dialysis: As seen in Table 9 and 10, kidney disease 
targeted scale ranged from 40.39to 81.37 in the possible of 0-100 scores. 
The 36 items health scale ranged from 21.31to 54.02. In kidney disease 
targeted scales burden of kidney disease (27.41±17.06), cognitive 
function (72.91±18.19), quality of social interaction (77.66±20.42), Effects 
of kidney disease (66.13±14.07), work status (43.43±26.15) whereas 
symptom/problem list (81.37±12.22), Sleep (65.88±22.28) and social 
support (86.15 ± 22.71). SF36 items health survey scales indicated that 
physical function (45.66± 25.17), role physical (39.13±21.67), role 
emotional (64.36±35.42), social support (78.11 ± 27.09), emotional well-
being (56.17±19.41), energy and fatigue (51.36 ± 10.39), general health 
(24.17 ±11.65) had a mean score below 50, but pain (51.66 ± 34.33) 
scored above 50. 
CRF patients on dialysis: The kidney disease targeted scales ranged from 
25.63 to 78.30 in the possible (0-100) scores. Kidney disease targeted 
scales showed that burden of kidney disease (34.15±21.07), Quality of 
social interaction (75.91±19.72) cognitive function (65.52±20.17), effects 
of kidney disease (74.66±13.44), work status (40.39±32.62) had mean 
score below 50 whereas symptom/problem list (77.35±12.25), sleep 
(65.22±18.37), social support (78.21±23.86) had mean score of above 
50.The 36 items health survey scales such as physical function 
(50.17±38.11), role physical (45.66±31.00), role emotional (68.17±30.47), 
social function (68.66±28.38), emotional well-being (55.41±18.66), 
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energy/fatigue (40.66±15.33), general health (30.66±15.14) had a mean 
score below 50. On the other pain (59.13±33.52) had mean score of above 
50. 
Overall, there was no significant change in the KDQOL-SFTM scores 
among patients with CRF patients on dialysis and CRF patients not on 
dialysis. Comparison of mean score as shown in Table 9 and 10, between 
CRF-D and CRF-ND groups revealed that quality of social interaction, 
role emotional, emotional well-being had a significant difference (p< 0.05) 
Apart from the physical, clinical, and functional parameters, factors such 
as the socio-cultural environment, economic status, emotional status, 
accessibility to medical care,and spiritual attitudes possibly play a 
significant role inan individual’s perception of life and disease.114,119-
121These parameters could not be assessed with the current toolfor 
HRQOL. 
Some limitations of the present study are the relatively small sample size 
to detect significant differences betweenthe stages of CKD and the 
difficulties we encountered inrecruiting subjects in the initial stages of 
the disease. The cross-sectional design of the study only permitted us to 
determine associations between variables and not causal relationships. 
Thus, longitudinal studies that take intoaccount qualitative assessments 
should be conducted toseek a better understanding of the influence of 
the progression of CKD on QOL. 
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8. CONCLUSION 
The proper measures of QOL in patients with renal disease are unknown. 
Measures include subjective and objective tools, and generic and disease-
specific scales. The past several years have witnessed an explosion in the 
number of studies and the populations of patients with CKD in which 
various aspects of HRQOL have been assessed. It is clear that the many 
QOL measures are intertwined. A challenge remains to make these 
domains clinically meaningful. Use of KDQOL-SFTM as a QOL 
assessment tool, may be valuable in the global assistance of these 
patients and allow timely health care intervention in the course of the 
disease. Our findings show that some symptom burden was higher in the 
non-dialysis group, compared to the dialysis group but most of the 
symptoms are did not reach statistical significance.  Similarly, there was 
no significant change in the KDQOL-SFTM scores among patients with 
CRF patients on dialysis and CRF patients not on dialysis. Results 
obtained from the use of KDQOL-SFTM in CRF patients undergoing 
dialysis and not on dialysis supports the reliability of the instrument in 
study area population. Hence, KDQOL-SFTM would help physicians in 
routine monitoring of patient’s perception of their wellbeing as it forms 
an integral part to impart better patient care. A better understanding of 
HRQoL and its determinants would help to formulate individualized 
treatment strategies. There is a compelling need for further research to 
better define the spectrum of changes in symptom burden and physical 
performance among patients started on maintenance dialysis. Such 
research will crucially inform the discussion between clinicians and 
patients in the shared decision making process around the timing of 
dialysis initiation. 
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INFORMATION FOR PATIENT 
 
Dear participant, 
  I Mr. SAIFUL ISLAM.M, [REG.No. 261540210]  student of  
J.K.K.Nattraja College of Pharmacy, Kumarapalayam currently 
conducting a project entitled “Assessment of Quality Of Life in Dialysis 
and Non-Dialysis Chronic Kidney Disease Patients”    for the partial  
fulfillment  for  the  award  of  Degree  of Master  of  Pharmacy  in  
Pharmacy  Practice.   
As the part of project we need to collect data from you including socio-
demographic details, symptoms of disease, answers regarding your quality 
of life and Medications prescribed. 
We will appreciate very much if you could kindly assist us to collect 
your medical data’s. However identifiable personal data’s will not be 
disclosed. 
Thank you very much for your kind participation. 
CONSENT FORM 
I, ____________________________, have read and understand the above 
information. I have agreed to allow my data to be collected for the project 
work. 
_______________________________    ____________________ 
Signature of participant                              Date 
 
_______________________________    
Signature of translator 
DATAENTRY 
 
Name:                       Height: 
Age:                            Weight: 
Sex:          BMI:      
Chronic Renal Failure: 
  Non-Dialysis        [Stage1      Stage 2        Stage 3       Stage 4       Stage 5     
]  
   Dialysis           [Hemodialysis         Peritoneal Dialysis       ] 
Marital Status: 
     Married         Divorced       Single  
Educational status: 
          Illiterate        School          Degree  
Monthly Income (Rs): 
   <5000          5000 – 15000         >15000 
Co-morbid diseases: 
       Hypertension  
       Diabetes mellitus   
       Ischemic Heart Disease  
       Anaemia  
       Others  
Laboratory Data: 
Sl.no Laboratory Parameter Values 
1 Hb(g/dl)  
2 Serum Urea(mg/dl)  
3 Serum calcium (mg/dl)  
4 Serum albumin (mg/dl)  
5 Serum Phosphorous 
(mg/dl) 
 
 
 
Prevalence of symptoms: 
Sl.no Prevalence of 
symptoms 
 
1 Feeling tired and lack of 
energy 
 
2 Worrying  
3 Itching  
4 Trouble in sleep  
5 Feeling depressed  
6 Bone and joint pain  
7 Muscle cramps  
8 Dry mouth  
9 Constipation  
10 Swelling legs  
11 Feeling nervous  
12 Headache  
13 Diarrhea  
14 Decreased appetite  
15 Cough  
16 Nausea  
17 Vomiting  
18 Numbness in feet  
19 Suppressed breathing  
20 Decreased interest in sex  
 
Page 1
Your Health
This survey includes a wide variety of questions about your health and
your life.  We are interested in how you feel about each of these issues.
1. In general, would you say your health is:  [Mark an  in the one box
that best describes your answer.]
Excellent Very good Good Fair Poor
t t t t t
   1    2    3    4    5
The following items are about activities you might do during a typical
day.  Does your health now limit you in these activities?  If so, how
much?  [Mark an  in a box on each line.]
Yes,
limited a
lot
Yes,
limited a
little
No, not
limited
at all
2. Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or
playing golf ....................................................  1.........  2 ........  3
3. Climbing several flights of stairs ......................  1.........  2 ........  3
Kidney Disease and Quality of Life (KDQOL™-36)
Page 2
During the past 4 weeks, have you had any of the following problems
with your work or other regular daily activities as a result of your
physical health?
Yes No
t t
4. Accomplished less than you would like................  1 .........  2
5. Were limited in the kind of work or other
activities .............................................................  1 .........  2
During the past 4 weeks, have you had any of the following problems
with your work or other regular daily activities as a result of any
emotional problems (such as feeling depressed or anxious)?
Yes No
t t
6. Accomplished less than you would like................  1 .........  2
7. Didn’t do work or other activities as carefully as
usual ..................................................................  1 .........  2
8. During the past 4 weeks, how much did pain interfere with your
normal work (including both work outside the home and
housework)?
Not at all A little bit Moderately Quite a bit Extremely
t t t t t
   1    2    3    4    5
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These questions are about how you feel and how things have been with
you during the past 4 weeks.  For each question, please give the one
answer that comes closest to the way you have been feeling.
How much of the time during the past 4 weeks…
All
 of the
time
Most
of the
time
A good
bit
 of the
time
Some
of the
time
A little
of the
time
None
of the
time
t t t t t t
9. Have you felt calm and
peaceful?......................  1........  2 .......  3........  4 .......  5 .......  6
10. Did you have a lot of
energy? ........................  1........  2 .......  3........  4 .......  5 .......  6
11. Have you felt
downhearted and blue? .  1........  2 .......  3........  4 .......  5 .......  6
12. During the past 4 weeks, how much of the time has your physical
health or emotional problems interfered with your social activities
(like visiting with friends, relatives, etc.)?
All
of the time
Most
of the time
Some
of the time
A little
of the time
None
of the time
t t t t t
   1    2    3    4    5
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Your Kidney Disease
How true or false is each of the following statements for you?
Definitely
true
Mostly
true
Don’t
know
Mostly
false
Definitely
false
13. My kidney
disease interferes
too much with my
life ........................
t t t t t
 1 ...........  2 ...........  3 ...........  4 ...........  5
14. Too much of my
time is spent
dealing with my
kidney disease.......  1 ...........  2 ...........  3 ...........  4 ...........  5
15. I feel frustrated
dealing with my
kidney disease.......  1 ...........  2 ...........  3 ...........  4 ...........  5
16. I feel like a burden
on my family .........
 1 ...........  2 ...........  3 ...........  4 ...........  5
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      During the past 4 weeks, to what extent were you bothered by each
of the following?
Not at all
bothered
Somewhat
bothered
Moderately
bothered
Very much
bothered
Extremely
bothered
t t t t t
17. Soreness in your
muscles? ...............  1 ............  2 ...........  3 ............  4 ...........  5
18. Chest pain? ...........  1 ............  2 ...........  3 ............  4 ...........  5
19. Cramps? ...............  1 ............  2 ...........  3 ............  4 ...........  5
20. Itchy skin?.............  1 ............  2 ...........  3 ............  4 ...........  5
21. Dry skin?...............  1 ............  2 ...........  3 ............  4 ...........  5
22. Shortness of
breath?..................  1 ............  2 ...........  3 ............  4 ...........  5
23. Faintness or
dizziness?..............  1 ............  2 ...........  3 ............  4 ...........  5
24. Lack of appetite?...  1 ............  2 ...........  3 ............  4 ...........  5
25. Washed out or
drained?................  1 ............  2 ...........  3 ............  4 ...........  5
26. Numbness in
hands or feet?........  1 ............  2 ...........  3 ............  4 ...........  5
27. Nausea or upset
stomach?...............  1 ............  2 ...........  3 ............  4 ...........  5
28
a
. (Hemodialysis patient only)
Problems with
your access site? ...  1 ............  2 ...........  3 ............  4 ...........  5
28
b
. (Peritoneal dialysis patient only)
Problems with
your catheter site?..  1 ............  2 ...........  3 ............  4 ...........  5
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Effects of Kidney Disease on Your Daily Life
Some people are bothered by the effects of kidney disease on their
daily life, while others are not.  How much does kidney disease
bother you in each of the following areas?
Not at all
bothered
Somewhat
bothered
Moderately
bothered
Very much
bothered
Extremely
bothered
t t t t t
29. Fluid restriction?....  1 ............  2 ...........  3 ............  4 ...........  5
30. Dietary restriction?.
 1 ............  2 ...........  3 ............  4 ...........  5
31. Your ability to
work around the
house? ..................  1 ............  2 ...........  3 ............  4 ...........  5
32. Your ability to
travel? ...................  1 ............  2 ...........  3 ............  4 ...........  5
33. Being dependent
on doctors and
other medical
staff?.....................  1 ............  2 ...........  3 ............  4 ...........  5
34. Stress or worries
caused by kidney
disease? ................  1 ............  2 ...........  3 ............  4 ...........  5
35. Your sex life? ........  1 ............  2 ...........  3 ............  4 ...........  5
36. Your personal
appearance? ..........  1 ............  2 ...........  3 ............  4 ...........  5
